Kun‐Ling Ma
- Nephrology top 1%
- Chronic Kidney Disease and Diabetes 15
- Renal Diseases and Glomerulopathies 15
- Dialysis and Renal Disease Management 6
- Parathyroid Disorders and Treatments 4
- Cancer Research top 10%
- Molecular Biology top 10%
- Inflammasome and immune disorders 8
- Connective Tissue Growth Factor Research 6
- Extracellular vesicles in disease 4
- Clinical Biochemistry top 5%
-
- Renin-Angiotensin System Studies 5
- Co-authors
- Bi‐Cheng LiuLin‐Li LvRi‐Ning TangYi WenYuhan CaoHong LiuMin XuTao‐Tao Tang
- Journals
- Acta Pharmacologica Sinica (9 papers)Journal of Cellular Biochemistry (5 papers)The International Journal of Biochemistry & Cell Biology (3 papers)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Kun‐Ling Ma
60 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 103
- Nephrology 639
- Cancer Research 223
- Molecular Biology 933
- Clinical Biochemistry 78
- Immunology 212
Countries citing papers authored by Kun‐Ling Ma
This map shows the geographic impact of Kun‐Ling Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun‐Ling Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun‐Ling Ma more than expected).
Fields of papers citing papers by Kun‐Ling Ma
This network shows the impact of papers produced by Kun‐Ling Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun‐Ling Ma. The network helps show where Kun‐Ling Ma may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kun‐Ling Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 24 | |
| 2 | 2020 | 6 | |
| 3 | 2020 | 69 | |
| 4 | 2019 | 11 | |
| 5 | 2018 | 63 | |
| 6 | 2018 | 34 | |
| 7 | 2017 | 23 | |
| 8 | 2016 | 1 | |
| 9 | 2016 | 20 | |
| 10 | 2015 | 65 | |
| 11 | 2015 | 23 | |
| 12 | 2015 | 93 | |
| 13 | 2014 | 90 | |
| 14 | 2013 | 169 | |
| 15 | Inhibition of integrin-linked kinase by angiotensin II receptor antagonist, irbesartan attenuates podocyte injury in diabetic rats. | 2012 | 12 |
| 16 | 2011 | 47 | |
| 17 | 2011 | 31 | |
| 18 | 2011 | 60 | |
| 19 | 2010 | 47 | |
| 20 | 2005 | 14 |
About Kun‐Ling Ma
Kun‐Ling Ma is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Family Practice, having authored 60 papers that have together received 1.7k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (15 papers), Renal Diseases and Glomerulopathies (15 papers), Inflammasome and immune disorders (8 papers), Dialysis and Renal Disease Management (6 papers), Connective Tissue Growth Factor Research (6 papers), Renin-Angiotensin System Studies (5 papers), Parathyroid Disorders and Treatments (4 papers) and Extracellular vesicles in disease (4 papers). The work is most often cited by research in Nephrology (639 citations), Cancer Research (223 citations) and Molecular Biology (933 citations). Kun‐Ling Ma has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Bi‐Cheng Liu, Lin‐Li Lv, Ri‐Ning Tang, Yi Wen, Yuhan Cao, Hong Liu, Min Xu, Tao‐Tao Tang, Jie Ni and Hai-Feng Ni. Their work appears in journals such as Acta Pharmacologica Sinica, Journal of Cellular Biochemistry, The International Journal of Biochemistry & Cell Biology, International Journal of Cardiology and The American Journal of the Medical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.